Adverse events · People of any age with caries (including demineralisation in non-cavitated carious lesions); the caries may affect any single tooth…
1 finding from 1 review
Patient satisfaction · People of any age with caries (including demineralisation in non-cavitated carious lesions); the caries may affect any single tooth…
1 finding from 1 review
Abu-Naba'a 2003 reported participants' state of anxiety, comparing ozone treatment with traditional dental interventions (injection, drilling, filling); because no participant was randomised between ozone and drilling…
1 study
GRADE not reported
Further conventional dental treatment (filling and drilling) (binary yes/no) · People of any age with caries (including demineralisation in non-cavitated carious lesions); the caries may affect any single tooth…
The review found no eligible studies for this question.
1 finding from 1 review
Costs · People of any age with caries (including demineralisation in non-cavitated carious lesions); the caries may affect any single tooth…
The review found no eligible studies for this question.
1 finding from 1 review
Pain (assessed by the patient) · People of any age with caries (including demineralisation in non-cavitated carious lesions); the caries may affect any single tooth…
The review found no eligible studies for this question.
1 finding from 1 review
Caries progression/regression (clinical severity index, log(e) ECM and log(e) DIAGNOdent scores) · People of any age with caries (including demineralisation in non-cavitated carious lesions); the caries may affect any single tooth…
1 finding from 1 review
No consistent trend of benefit or harm following ozone was seen across the outcome measures in any of the three studies; analyses were conducted at the lesion level (not independent of the person), so data were not…
3 studies · 137 participants
GRADE not reported
Time to intervention · People of any age with caries (including demineralisation in non-cavitated carious lesions); the caries may affect any single tooth…
The review found no eligible studies for this question.
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid leads to lower failure to maintain clinical or endoscopic remission compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in withdrawal due to adverse event compared with sulfasalazine (moderate certainty).
1 finding from 1 review
Exclusion/withdrawal after entry · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid probably leads to higher exclusion/withdrawal after entry compared with sulfasalazine (moderate certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in failure to maintain clinical or endoscopic remission compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in adverse event compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether oral 5‐aminosalicylic acid changes withdrawal due to adverse events compared with comparator 5‐aminosalicylic acid formulation (very low certainty).
1 finding from 1 review
Exclusion/withdrawal after entry · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in exclusion/withdrawal after entry compared with comparator 5‐aminosalicylic acid formulation (moderate certainty).
1 finding from 1 review
Adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review